Bright Minds Biosciences Inc. (CSE:DRUG)
Canada
· Delayed Price · Currency is CAD 106.49
+6.49 (6.49%)
At close: Dec 5, 2025
Bright Minds Biosciences Balance Sheet
Financials in millions CAD. Fiscal year is October - September.
Millions CAD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2019 |
| Cash & Equivalents | 51.39 | 5.72 | 6.75 | 11.63 | 19.76 | 0.8 | Upgrade
|
| Cash & Short-Term Investments | 51.39 | 5.72 | 6.75 | 11.63 | 19.76 | 0.8 | Upgrade
|
| Cash Growth | 730.14% | -15.23% | -41.97% | -41.15% | 2370.22% | 900.02% | Upgrade
|
| Other Receivables | 0.27 | 0.05 | 0.04 | 0.16 | 0.11 | - | Upgrade
|
| Receivables | 0.27 | 0.05 | 0.04 | 0.16 | 0.11 | - | Upgrade
|
| Prepaid Expenses | 0.71 | 0.22 | 0.03 | 0.16 | 0.17 | 0.08 | Upgrade
|
| Total Current Assets | 52.37 | 5.99 | 6.81 | 11.95 | 20.04 | 0.88 | Upgrade
|
| Property, Plant & Equipment | 0.13 | 0.12 | 0.07 | 0.14 | - | - | Upgrade
|
| Other Intangible Assets | - | - | - | - | 0 | 0 | Upgrade
|
| Total Assets | 52.5 | 6.1 | 6.88 | 12.09 | 20.04 | 0.88 | Upgrade
|
| Accounts Payable | 0.51 | 0.41 | 0.18 | 1.25 | 0.6 | 0.14 | Upgrade
|
| Accrued Expenses | 0.02 | 0.04 | 0.03 | 0.16 | 0.04 | 0.01 | Upgrade
|
| Current Portion of Leases | 0.08 | 0.08 | 0.07 | 0.07 | - | - | Upgrade
|
| Total Current Liabilities | 0.6 | 0.53 | 0.28 | 1.47 | 0.64 | 0.15 | Upgrade
|
| Long-Term Leases | 0.06 | 0.04 | - | 0.07 | - | - | Upgrade
|
| Total Liabilities | 0.67 | 0.57 | 0.28 | 1.54 | 0.64 | 0.15 | Upgrade
|
| Common Stock | 89.91 | 35.42 | 33.91 | 32.24 | 27.08 | 0.98 | Upgrade
|
| Retained Earnings | -42.49 | -34.35 | -31.55 | -24.17 | -9.21 | -0.56 | Upgrade
|
| Comprehensive Income & Other | 4.41 | 4.46 | 4.23 | 2.48 | 1.53 | 0.31 | Upgrade
|
| Shareholders' Equity | 51.83 | 5.54 | 6.6 | 10.54 | 19.4 | 0.73 | Upgrade
|
| Total Liabilities & Equity | 52.5 | 6.1 | 6.88 | 12.09 | 20.04 | 0.88 | Upgrade
|
| Total Debt | 0.14 | 0.12 | 0.07 | 0.14 | - | - | Upgrade
|
| Net Cash (Debt) | 51.25 | 5.6 | 6.67 | 11.49 | 19.76 | 0.8 | Upgrade
|
| Net Cash Growth | 729.74% | -16.08% | -41.90% | -41.86% | 2370.22% | 900.02% | Upgrade
|
| Net Cash Per Share | 8.28 | 1.30 | 1.79 | 4.65 | 11.01 | 1.11 | Upgrade
|
| Filing Date Shares Outstanding | 7.08 | 6.99 | 4.46 | 3.74 | 2.37 | 1.27 | Upgrade
|
| Total Common Shares Outstanding | 7.08 | 4.52 | 3.77 | 3.52 | 2.37 | 0.95 | Upgrade
|
| Working Capital | 51.76 | 5.46 | 6.53 | 10.48 | 19.4 | 0.73 | Upgrade
|
| Book Value Per Share | 7.32 | 1.22 | 1.75 | 3.00 | 8.20 | 0.77 | Upgrade
|
| Tangible Book Value | 51.83 | 5.54 | 6.6 | 10.54 | 19.4 | 0.73 | Upgrade
|
| Tangible Book Value Per Share | 7.32 | 1.22 | 1.75 | 3.00 | 8.20 | 0.77 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.